{
  "id": 419102,
  "title": "Earnings call transcript: Imricor posts tiny Q2 2026 revenue as U.S. launch begins",
  "url": "https://urgent.news/2026/08/09/earnings-call-transcript-imricor-posts-tiny-q2-2026-revenue-as-u-s",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-09T23:44:06.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/earnings-call-transcript-imricor-posts-tiny-q2-2026-revenue-as-us-launch-begins-93CH-4847768"
  },
  "original_language": "en",
  "account": "Imricor Medical Systems reported a slight decline in its second-quarter revenue, totaling $61,000, down about 6% from the same period last year. The company also posted an adjusted net loss of AUD 7.0 million, reflecting a significant widening from AUD 5.1 million in the prior year. This loss is attributed to higher operating expenses related to marketing, staffing, and production capacity expansion. Despite the small revenue figure, the company's U.S. launch of its MR-guided cardiac intervention platform marks a significant step forward. Imricor has received four FDA clearances and seen progress in clinical trials, but the company remains in the early stages of commercialization. Management expressed optimism about the second half of 2026, anticipating a revenue inflection driven by U.S. NorthStar sales and European site expansion.",
  "summary": null,
  "key_points": [
    "Imricor Medical Systems reported $61,000 revenue, a 6% decline from Q2 2025",
    "Company posted AUD 7.0 million adjusted net loss, up from AUD 5.1 million",
    "U.S. launch of MR-guided cardiac intervention platform marks significant progress"
  ],
  "editors_take": "Imricor's widening net loss and stagnant revenue are offset by progress in its US commercialization efforts, positioning the company for potential revenue growth in the second half of 2026.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}